Lymphocyte-derived cytokines in inflammatory arthritis

Autoimmunity

Volumn 41, Issue 3, 2008, Pages 230-238

  Horwood, Nicole ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Interferon; Osteoblast; Osteoclast; RANKL; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ANTIRHEUMATIC AGENT; ATLIZUMAB; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DENOSUMAB; ETANERCEPT; GAMMA INTERFERON; GLYCOPROTEIN GP 130; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 7; METHOTREXATE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT IMMUNOGLOBULIN FC FRAGMENT OSTEOPROTEGERIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BODY MASS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; IMMOBILIZATION; IMMUNOMODULATION; IMMUNOPATHOLOGY; JUVENILE RHEUMATOID ARTHRITIS; MENOPAUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VERTEBRA FRACTURE;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CYTOKINES; HUMANS; LYMPHOCYTES; OSTEOCLASTS;

EID: 41449087043     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930701694766     Document Type: Review

References (61)

1. Wong, BR (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem, 272, pp. 25190-25194.
2. Yasuda, H. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 95, pp. 3597-3602.
3. Lacey, DL (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, pp. 165-176.
4. Horwood, NJ (1999) Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun, 265, pp. 144-150.
5. Kong, YY (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402, pp. 304-309.
6. Kong, YY (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397, pp. 315-323.
7. Shinoda, K. (2003) Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes. Bone, 33, pp. 711-720.
8. Weitzmann, MN and Pacifici, R. (2005) The role of T lymphocytes in bone metabolism. Immunol Rev, 208, pp. 154-168.
9. Sinigaglia, L., Varenna, M., Girasole, G. and Bianchi, G. (2006) Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am, 32, pp. 631-658.
10. Feldmann, M. (2005) Anti-TNF therapy: Where have we got to in 2005?. J Autoimmun, 25, pp. 26-28.
11. Klareskog, L., Forsum, U., Scheynius, A., Kabelitz, D. and Wigzell, H. (1982) Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA, 79, pp. 3632-3636.
12. Ranges, GE, Sriram, S. and Cooper, SM (1985) Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med, 162, pp. 1105-1110.
13. Toh, ML and Miossec, P. (2007) The role of T cells in rheumatoid arthritis: New subsets and new targets. Curr Opin Rheumatol, 19, pp. 284-288.
14. Ernst, CW (2007) Diminished forkhead box P3/CD25 double-positive T regulatory cells are associated with the increased nuclear factor-kappaB ligand (RANKL+) T cells in bone resorption lesion of periodontal disease. Clin Exp Immunol, 148, pp. 271-280.
15. Kim, YG (2007) Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem Biophys Res Commun, 357, pp. 1046-1052.
16. Young, N., Mikhalkevich, N., Yan, Y., Chen, D. and Zheng, WP (2005) Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma. J Immunol, 175, pp. 8287-8295.
17. Horwood, NJ, Elliott, J., Martin, TJ and Gillespie, MT (1998) Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology, 139, pp. 4743-4746.
18. Geusens, PP (2006) The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum, 54, pp. 1772-1777.
19. Li, Y. (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood, 109, pp. 3839-3848.
20. Schett, G. (2003) Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum, 48, pp. 2042-2051.
21. Romas, E. (2002) Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol, 161, pp. 1419-1427.
22. Lam, J. (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest, 106, pp. 1481-1488.
23. Redlich, K. (2002) Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum, 46, pp. 785-792.
24. Chen, YF (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess, 10, pp. 1-229.
25. Kaneki, H. (2006) Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem, 281, pp. 4326-4333.
26. Wei, S., Kitaura, H., Zhou, P., Ross, FP and Teitelbaum, SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest, 115, pp. 282-290.
27. Rannou, F., Francois, M., Corvol, MT and Berenbaum, F. (2006) Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine, 73, pp. 29-36.
28. Kavanaugh, A. (2006) Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther, 23, pp. 208-217.
29. Zwerina, J. (2004) Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum, 50, pp. 277-290.
30. Kurihara, N. and Roodman, GD (1990) Interferons-alpha and -gamma inhibit interleukin-1 beta-stimulated osteoclast-like cell formation in long-term human marrow cultures. J Interferon Res, 10, pp. 541-547.
31. Boissier, MC (1995) Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol, 25, pp. 1184-1190.
32. Gao, Y. (2007) IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest, 117, pp. 122-132.
33. Cook, AD, Braine, EL, Campbell, IK, Rich, MJ and Hamilton, JA (2001) Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): Requirement for GM-CSF in the effector phase of disease. Arthritis Res, 3, pp. 293-298.
34. Hodge, JM (2004) Osteoclastic potential of human CFU-GM: Biphasic effect of GM-CSF. J Bone Miner Res, 19, pp. 190-199.
35. Horwood, NJ, Elliott, J., Martin, TJ and Gillespie, MT (2001) IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol, 166, pp. 4915-4921.
36. Bombardieri, M., McInnes, IB and Pitzalis, C. (2007) Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. Expert Opin Biol Ther, 7, pp. 31-40.
37. Quinn, JM (2001) Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res, 16, pp. 1787-1794.
38. Mendez-Davila, C., Garcia-Moreno, C., Turbi, C. and de la Piedra, C. (2004) Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures. J Endocrinol Invest, 27, pp. 904-912.
39. Koenders, MI (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9 and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum, 52, pp. 3239-3247.
40. Kotake, S. (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest, 103, pp. 1345-1352.
41. Lubberts, E., Koenders, MI and Berg, WB van den (2005) The role of T-cell interleukin-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Res Ther, 7, pp. 29-37.
42. Koenders, MI (2006) Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol, 176, pp. 6262-6269.
43. Ogata, Y. (1999) A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2. J Immunol, 162, pp. 2754-2760.
44. Harada, S. (1999) Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum, 42, pp. 1508-1516.
45. Baslund, B. (2005) Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum, 52, pp. 2686-2692.
46. Mirosavljevic, D. (2003) T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res, 18, pp. 984-993.
47. Yamada, A. (2007) Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology, 120, pp. 573-579.
48. Lubberts, E. (2000) IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest, 105, pp. 1697-1710.
49. Palmqvist, P., Persson, E., Conaway, HH and Lerner, UH (2002) IL-6, leukemia inhibitory factor and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol, 169, pp. 3353-3362.
50. Plater-Zyberk, C. (2001) Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum, 44, pp. 2697-2702.
51. Smolen, JS and Maini, RN (2006) Interleukin-6: A new therapeutic target. Arthritis Res Ther, 8, p. S5.
52. Hartgring, SA, Bijlsma, JW, Lafeber, FP and van Roon, JA (2006) Interleukin-7 induced immunopathology in arthritis. Ann Rheum Dis, 65, p. iii69.
53. Toraldo, G., Roggia, C., Qian, WP, Pacifici, R. and Weitzmann, MN (2003) IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA, 100, pp. 125-130.
54. Weitzmann, MN, Roggia, C., Toraldo, G., Weitzmann, L. and Pacifici, R. (2002) Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest, 110, pp. 1643-1650.
55. Ryan, MR (2005) An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA, 102, pp. 16735-16740.
56. Xu, LX (1995) Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. J Cell Physiol, 165, pp. 624-629.
57. Evans, KE and Fox, SW (2007) Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol, 8, p. 4.
58. Liu, D., Yao, S. and Wise, GE (2006) Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle. Eur J Oral Sci, 114, pp. 42-49.
59. Hsu, YH (2006) Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum, 54, pp. 2722-2733.
60. Ikeuchi, H. (2005) Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum, 52, pp. 1037-1046.
61. Joosten, LA (2006) IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA, 103, pp. 3298-3303.